161 related articles for article (PubMed ID: 17412886)
1. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.
Yong AS; Rezvani K; Savani BN; Eniafe R; Mielke S; Goldman JM; Barrett AJ
Blood; 2007 Jul; 110(2):770-5. PubMed ID: 17412886
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.
Yong AS; Keyvanfar K; Eniafe R; Savani BN; Rezvani K; Sloand EM; Goldman JM; Barrett AJ
Leukemia; 2008 Sep; 22(9):1721-7. PubMed ID: 18548092
[TBL] [Abstract][Full Text] [Related]
3. Improved outcome following allogeneic stem cell transplantation in chronic myeloid leukemia is associated with higher expression of BMI-1 and immune responses to BMI-1 protein.
Yong AS; Stephens N; Weber G; Li Y; Savani BN; Eniafe R; Keyvanfar K; Kurlander R; Rezvani K; Barrett AJ
Leukemia; 2011 Apr; 25(4):629-37. PubMed ID: 21252986
[TBL] [Abstract][Full Text] [Related]
4. Lymphodepletion is permissive to the development of spontaneous T-cell responses to the self-antigen PR1 early after allogeneic stem cell transplantation and in patients with acute myeloid leukemia undergoing WT1 peptide vaccination following chemotherapy.
Rezvani K; Yong AS; Mielke S; Savani BN; Jafarpour B; Eniafe R; Le RQ; Musse L; Boss C; Childs R; John Barrett A
Cancer Immunol Immunother; 2012 Jul; 61(7):1125-36. PubMed ID: 22198310
[TBL] [Abstract][Full Text] [Related]
5. KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.
van der Meer A; Schaap NP; Schattenberg AV; van Cranenbroek B; Tijssen HJ; Joosten I
Mol Immunol; 2008 Aug; 45(13):3631-8. PubMed ID: 18555529
[TBL] [Abstract][Full Text] [Related]
6. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
[TBL] [Abstract][Full Text] [Related]
7. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation.
Rezvani K; Grube M; Brenchley JM; Sconocchia G; Fujiwara H; Price DA; Gostick E; Yamada K; Melenhorst J; Childs R; Hensel N; Douek DC; Barrett AJ
Blood; 2003 Oct; 102(8):2892-900. PubMed ID: 12829610
[TBL] [Abstract][Full Text] [Related]
8. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes.
Falkenburg JH; Wafelman AR; Joosten P; Smit WM; van Bergen CA; Bongaerts R; Lurvink E; van der Hoorn M; Kluck P; Landegent JE; Kluin-Nelemans HC; Fibbe WE; Willemze R
Blood; 1999 Aug; 94(4):1201-8. PubMed ID: 10438707
[TBL] [Abstract][Full Text] [Related]
9. Prophylactic transfer of BCR-ABL-, PR1-, and WT1-reactive donor T cells after T cell-depleted allogeneic hematopoietic cell transplantation in patients with chronic myeloid leukemia.
Bornhäuser M; Thiede C; Platzbecker U; Kiani A; Oelschlaegel U; Babatz J; Lehmann D; Hölig K; Radke J; Tuve S; Wermke M; Wehner R; Jähnisch H; Bachmann MP; Rieber EP; Schetelig J; Ehninger G; Schmitz M
Blood; 2011 Jun; 117(26):7174-84. PubMed ID: 21540460
[TBL] [Abstract][Full Text] [Related]
10. A frameshift polymorphism in P2X5 elicits an allogeneic cytotoxic T lymphocyte response associated with remission of chronic myeloid leukemia.
de Rijke B; van Horssen-Zoetbrood A; Beekman JM; Otterud B; Maas F; Woestenenk R; Kester M; Leppert M; Schattenberg AV; de Witte T; van de Wiel-van Kemenade E; Dolstra H
J Clin Invest; 2005 Dec; 115(12):3506-16. PubMed ID: 16322791
[TBL] [Abstract][Full Text] [Related]
11. Individualized intervention guided by BCR-ABL transcript levels after HLA-identical sibling donor transplantation improves HSCT outcomes for patients with chronic myeloid leukemia.
Huang XJ; Xu LP; Liu KY; Liu DH; Chen H; Liu YR; Chen YH; Han W; Wang Y
Biol Blood Marrow Transplant; 2011 May; 17(5):649-56. PubMed ID: 20691800
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.
Molldrem JJ; Clave E; Jiang YZ; Mavroudis D; Raptis A; Hensel N; Agarwala V; Barrett AJ
Blood; 1997 Oct; 90(7):2529-34. PubMed ID: 9326217
[TBL] [Abstract][Full Text] [Related]
13. Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.
Lacey SF; La Rosa C; Kaltcheva T; Srivastava T; Seidel A; Zhou W; Rawal R; Hagen K; Krishnan A; Longmate J; Andersson HA; St John L; Bhatia R; Pullarkat V; Forman SJ; Cooper LJ; Molldrem J; Diamond DJ
Blood; 2011 Aug; 118(8):2159-69. PubMed ID: 21719601
[TBL] [Abstract][Full Text] [Related]
14. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia.
Elmaagacli AH; Peceny R; Steckel N; Trenschel R; Ottinger H; Grosse-Wilde H; Schaefer UW; Beelen DW
Blood; 2003 Jan; 101(2):446-53. PubMed ID: 12393406
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with early molecular remission after T cell-depleted allogeneic stem cell transplantation for chronic myelogenous leukemia.
Savani BN; Rezvani K; Mielke S; Montero A; Kurlander R; Carter CS; Leitman S; Read EJ; Childs R; Barrett AJ
Blood; 2006 Feb; 107(4):1688-95. PubMed ID: 16131570
[TBL] [Abstract][Full Text] [Related]
16. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Stem Cell Transplantation for Patients with T315I BCR-ABL Mutated Chronic Myeloid Leukemia.
Xu LP; Xu ZL; Zhang XH; Chen H; Chen YH; Han W; Chen Y; Wang FR; Wang JZ; Wang Y; Yan CH; Mo XD; Liu KY; Huang XJ
Biol Blood Marrow Transplant; 2016 Jun; 22(6):1080-1086. PubMed ID: 26995693
[TBL] [Abstract][Full Text] [Related]
18. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity.
Rezvani K; Price DA; Brenchley JM; Kilical Y; Gostick E; Sconocchia G; Hansmann K; Kurlander R; Douek DC; Barrett AJ
Cytotherapy; 2007; 9(3):245-51. PubMed ID: 17464756
[TBL] [Abstract][Full Text] [Related]
19. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission.
Craddock C; Szydlo RM; Klein JP; Dazzi F; Olavarria E; van Rhee F; Pocock C; Cwynarski K; Apperley JF; Goldman JM
Blood; 2000 Jul; 96(1):86-90. PubMed ID: 10891435
[TBL] [Abstract][Full Text] [Related]
20. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
